Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin
- 1 February 2011
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 49 (2), 624-629
- https://doi.org/10.1128/jcm.02120-10
Abstract
The CLSI clinical breakpoint (CBP) for echinocandin susceptibility (S; MICs of ≤2 μg/ml) may classify isolates with acquired resistance (R) mutations as susceptible. Epidemiological cutoff values (ECVs) have been established to distinguish wild-type (WT) Candida strains from those that may exhibit R mutations. The CLSI-developed ECVs for anidulafungin, caspofungin, and micafungin were applied to 15,269 isolates of Candida spp. collected from over 100 centers worldwide between 2001 and 2009 to determine the frequency of non-WT strains of each species. The collection included 8,378 isolates of Candida albicans , 2,352 isolates of C. glabrata , 2,195 isolates of C. parapsilosis , 1,841 isolates of C. tropicalis , and 503 isolates of C. krusei . The mean percentages of non-WT isolates per year for anidulafungin, caspofungin, and micafungin, respectively, were as follows: for C. albicans , 0.3, 0.1, and 2.1; for C. glabrata , 0.8, 1.3, and 1.6; for C. parapsilosis , 0.0, 1.5, and 0.5; for C. tropicalis , 0.9, 0.7, and 0.9; and for C. krusei , 0.5, 6.4, and 3.5. We noted increases in the percentage of non-WT isolates, from 0.5% (2001) to 3.1% (2009) for caspofungin and C. parapsilosis , from 0.4% (2004) to 1.8% (2009) for anidulafungin and C. glabrata , from 2.4% (2004) to 5.7% (2009) for micafungin and C. krusei , and from 0.0% (2004) to 3.1% (2009) for micafungin and C. parapsilosis . No trends were noted for any species and drug when we used the CBP. Echinocandin CBPs are insensitive for detecting emerging R. Although uncommon, decreased S among Candida isolates was observed for each of the echinocandins and varied by species. Using ECVs is important in determining R trends among echinocandins and Candida .Keywords
This publication has 34 references indexed in Scilit:
- Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida StrainsAntimicrobial Agents and Chemotherapy, 2010
- Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant RecipientAntimicrobial Agents and Chemotherapy, 2010
- Echinocandin Susceptibility Testing ofCandidaSpecies: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest MediaAntimicrobial Agents and Chemotherapy, 2010
- Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility BreakpointAntimicrobial Agents and Chemotherapy, 2009
- Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target SpeciesAntimicrobial Agents and Chemotherapy, 2009
- Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2009
- Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic MalignanciesAntimicrobial Agents and Chemotherapy, 2008
- Mutations in the fks1 Gene in Candida albicans , C. tropicalis , and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2008
- Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia TreatmentAntimicrobial Agents and Chemotherapy, 2008
- Acquired resistance to echinocandins in Candida albicans: case report and reviewJournal of Antimicrobial Chemotherapy, 2007